Tranexamic Acid vs Hydroquinone for Melasma: A Complete Comparison Guide
Tranexamic acid and hydroquinone both reduce melasma pigmentation, but by different routes: hydroquinone blocks melanin production directly in the melanocyte, while tranexamic acid works upstream by reducing the signalling that drives melanocytes to overproduce. They are not interchangeable, and in Korean dermatology practice they are frequently used together rather than as alternatives.
Melasma is the single most frustrating pigmentary condition to treat because it relapses. Any guide that presents one agent as a cure is misrepresenting the condition. What follows is a mechanism-level comparison, realistic timelines, and the safety points that determine which agent suits which patient. See also our guide to comprehensive melasma treatment approaches in Korean clinics for how energy devices fit alongside topicals.
What melasma actually is, and why it relapses
Melasma is a chronic acquired hyperpigmentation, typically symmetrical, most often on the cheeks, forehead, upper lip and jawline. It reflects overactive melanocytes rather than more melanocytes, and it is driven by a combination of ultraviolet and visible light exposure, hormonal influence including pregnancy and oral contraceptives, heat, and genetic susceptibility.
Crucially, melasma involves the surrounding tissue, not just the pigment cell. Increased dermal vascularity, mast cell activity, and a disrupted basement membrane are all documented features. This is why treatments that only bleach the visible pigment give temporary results: the underlying driver is still running.
How hydroquinone works
Hydroquinone inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis. Less tyrosinase activity means less melanin produced by the melanocyte. It is the most extensively studied depigmenting agent and remains a reference standard against which others are measured.
Typical topical concentrations in clinical use range from 2% to 4%, with higher concentrations reserved for short courses under supervision. It is often compounded with a retinoid and a topical corticosteroid - the classic triple combination - which improves efficacy over hydroquinone alone in published comparisons.
Onset is usually gradual. Most protocols expect visible improvement over 8 to 12 weeks of consistent use, with the fullest effect later.
Hydroquinone's limitations and safety profile
Irritation. Erythema, stinging and dryness are common early, particularly in combination formulations containing a retinoid.
Post-inflammatory hyperpigmentation. Paradoxically, irritation itself can darken skin in higher Fitzpatrick types, undermining the treatment.
Exogenous ochronosis. A rare but disfiguring blue-grey discolouration associated with prolonged, high-concentration, unsupervised use. This is the main reason continuous long-term use is discouraged.
Rebound. Pigmentation commonly returns after stopping, sometimes rapidly, if sun protection and maintenance are not in place.
Regulatory status. Availability of over-the-counter hydroquinone varies by country. In Korea, higher-concentration preparations are prescription-controlled. Do not source it informally.
Because of ochronosis risk and rebound, standard practice is cyclical rather than continuous use: a defined treatment period, then a maintenance phase using a non-hydroquinone agent.
How tranexamic acid works
Tranexamic acid is a plasmin inhibitor, originally an antifibrinolytic drug used to reduce bleeding. Its effect in melasma appears to come from interrupting the plasminogen-plasmin pathway in keratinocytes, which reduces the release of inflammatory mediators such as arachidonic acid and prostaglandins that stimulate melanocytes. It also appears to reduce the dermal vascularity and mast cell activity that characterise melasma skin.
In other words, it addresses the upstream signalling rather than only the pigment factory. This mechanistic difference is why it is often effective in patients whose melasma has plateaued on hydroquinone.
It is used three ways: topically, by intradermal microinjection, and orally. Oral tranexamic acid has the strongest evidence base of the three for melasma, with multiple randomised trials and meta-analyses reporting meaningful reductions in melasma severity scores at low doses over roughly 8 to 12 weeks.
Tranexamic acid's limitations and safety profile
The oral route is where the safety conversation sits, because tranexamic acid is a systemic antifibrinolytic.
Thromboembolic risk. This is the central concern. Patients with a personal or family history of venous thromboembolism, thrombophilia, active malignancy, or who are on combined oral contraceptives, are generally not candidates. A proper history and, in some cases, screening is required before prescribing.
Common side effects. Gastrointestinal upset, reduced menstrual flow, and headache are reported at low doses.
Not for self-medication. Oral tranexamic acid for melasma is off-label in most jurisdictions and must be prescribed and monitored. Purchasing it online to self-treat is genuinely unsafe.
Topical efficacy is more modest. Topical tranexamic acid has a better safety profile but generally weaker and slower effects than oral in comparative studies.
Relapse. As with hydroquinone, pigmentation commonly returns after discontinuation without maintenance.
What most comparisons leave out: they are not competitors
English-language articles typically frame this as a choice. Korean dermatology practice generally does not. Because the two agents act at different points in the same pathway, combination protocols are common and comparative studies of combinations tend to outperform either agent alone.
A representative sequence in practice looks like this: strict photoprotection established first, then a defined hydroquinone-containing course for visible pigment reduction, oral or topical tranexamic acid running alongside or afterwards to suppress the driving signal, then transition to a non-hydroquinone maintenance regimen - typically azelaic acid, cysteamine, niacinamide, a retinoid, or topical tranexamic acid - held indefinitely.
Framing the question as "which one" tends to produce worse outcomes than framing it as "in what sequence, for how long, and what is the maintenance plan."
Where lasers and devices fit
Low-fluence Q-switched and picosecond laser toning is widely used in Korea for melasma and can accelerate visible clearance. It also carries a real risk of aggravating melasma or causing hypopigmentation if over-treated, particularly in higher Fitzpatrick types. Energy devices are best understood as an adjunct to a topical and systemic regimen, not a replacement for one. Any protocol that offers laser sessions without a photoprotection and maintenance plan is incomplete.
Photoprotection is not optional background advice
Both agents fail without it. Melasma responds to visible light and heat, not only UV, which means a conventional UV-only sunscreen is insufficient. Tinted sunscreens containing iron oxides provide visible-light protection and are specifically recommended in melasma. Broad-spectrum SPF 50, reapplication, physical shading and heat avoidance form the baseline on which everything else is built.
Frequently asked questions
Which works faster?
Both typically require 8 to 12 weeks for clear improvement. Hydroquinone may show earlier visible lightening of existing pigment; tranexamic acid tends to reduce recurrence and the inflammatory background. Neither works in days, and any product promising that should be treated with scepticism.
Can I take oral tranexamic acid while on the contraceptive pill?
This combination raises thromboembolic risk and is generally avoided. It must be discussed with the prescribing physician, who will weigh your full history. Do not make this decision independently.
Is hydroquinone banned?
Its regulatory status varies. Some jurisdictions restrict over-the-counter sale while permitting prescription use; Korea controls higher concentrations by prescription. It is not universally banned, but unsupervised long-term use is discouraged everywhere because of ochronosis risk.
Will my melasma come back?
Relapse is common with both agents, particularly with sun exposure, pregnancy, hormonal changes or heat exposure. Realistic expectation setting is that melasma is managed rather than cured, with maintenance therapy and photoprotection continued long term.
Can I use both at the same time?
Combination protocols are common in clinical practice and are generally supervised. Self-combining prescription agents without medical oversight is not advisable, particularly where the oral route is involved.
Planning treatment in Korea
If you are travelling for melasma treatment, plan for a course rather than a single visit. Ask for a written protocol covering the treatment phase, the maintenance phase, and what you will be taking home. Confirm whether any prescribed oral medication is legal to carry into your home country and whether you can obtain refills there. Ask specifically what the clinic's plan is if pigmentation rebounds after you return.
Sources and further reading
This article is general information and not medical advice. Melasma treatment, particularly with oral medication, requires assessment and prescription by a licensed physician.
Comments